Since obesity, HFpEF, and atrial fibrillation are interrelated, novel pharmacotherapies such as glucagon-like peptide 1 (GLP-1) receptor agonist might be proven a valuable addition in the therapeutic armamentarium for AF management. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.